Ambitious Entertainment Submits Proposal for Public Offering with U.S. Securities and Exchange Commission
With offices in Vancouver and Los Angeles, Ambitious Entertainment is incorporated in the state of Nevada and has recently delivered high-profile content, including the horror movie All My Friends Are Dead starring JoJo Siwa.
With a confident strategy of packaging premium IP-based film and television content for both domestic and international markets, Ambitious currently has ten projects in active development, each targeted for release between 2026 and 2027. The company's curated slate emphasizes high-concept IP, global talent partnerships, and scalable content designed to appeal to diverse audiences across major distribution platforms.
Co-President Kirk Shaw, 'Ambitious was founded with the goal of identifying breakout talent and IP with domestic and international appeal. We believe this public offering will allow us to expand new production and accelerate our current slate as we enter one of the most exciting periods in our company's history.'
The proposed offering comes amid renewed strength in the IPO market and growing investor appetite for content-driven businesses with scalable pipelines and valuable intellectual property. Ambitious aims to leverage public capital to finance production, expand distribution partnerships, and invest in strategic acquisitions across the media and entertainment landscape.
For updates on the offering and additional company news, please visit Ambitious.tv.
About Ambitious Entertainment
Ambitious Entertainment is a dynamic film and television company focused on the development, packaging, and production of premium entertainment for global audiences. With offices in Vancouver and Los Angeles, the company brings together a top-tier management team as well as A-list and emerging talent to deliver compelling stories across all major platforms.Contact: [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261024
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Brad Pitt's mom, Jane Etta Pitt, dies at 84
Brad Pitt's mom and occasional red carpet plus-one, Jane Etta Pitt, has died. She was 84. The matriarch, who formerly worked as a school counselor and appeared alongside her husband, William, and their Oscar-winning son at the 2012 Academy Awards, died earlier this week, according to TMZ. Representatives for the 61-year-old Oscar winner — who was also photographed with his parents at the 2014 premiere of ex-wife Angelina Jolie's premiere for 'Unbroken' — did not immediately respond to the Daily News' request for comment. Jane was remembered for having 'the biggest heart' and having 'cared deeply for everyone and everything, no questions asked,' said Sydney Pitt, who People identified as Brad's niece. 'She could keep up with all 14 of us grandkids without missing a beat. There was no limit to the love she gave, and everyone who met her felt it,' Sydney said. 'I don't know how we move forward without her. But I know she's still here in every brushstroke, every kind of gesture, every hummingbird. She was love in its purest form.' Pitt fans got a closer look at three generations of the family during the 'Unbroken' premiere, which he attended with both his mom and three of the six children he shares with 50-year-old Jolie. It's unclear how close Jane was to the A-listers' children in recent years, amid their nasty eight-year divorce and legal battle over their French winery. At least three of the exes' kids — daughters Shiloh and Zahara as well as son Maddox — have filed to drop Pitt from their surname. The movie star said 'hi to my mom' during a mid-June screening for the blockbuster 'F1,' telling 'Today' show host Savannah Guthrie, 'She watches you every morning.' He then blew a kiss to the camera, adding, 'To Jane Pitt, I love you.'
Yahoo
11 minutes ago
- Yahoo
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasib Company entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercialization Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2025, and provided an update on corporate progress. The company continues to make meaningful progress on its near-term strategic priorities: Execute pivotal trials with daraxonrasib monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) RASolute 302, a global Phase 3 trial of daraxonrasib in patients with previously treated PDAC, continues to enroll well. The company is winding down enrollment in the U.S. while continuing to enroll patients outside the U.S. to support global registration. The company expects to complete enrollment in this trial this year to enable an expected data readout in 2026. The company recently announced that daraxonrasib received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for previously treated metastatic PDAC in patients with KRAS G12 mutations. In RASolve 301, a global Phase 3 trial of daraxonrasib in patients with previously treated NSCLC, the company continues enrolling patients in the U.S. and is now activating trial sites in Europe and Japan. Advance daraxonrasib into earlier line randomized pivotal trials in patients with PDAC and NSCLC The company remains on track to initiate a registrational trial this year with daraxonrasib as first line treatment for patients with metastatic PDAC; this is planned as a three-arm trial comparing daraxonrasib or daraxonrasib plus chemotherapy to chemotherapy. Later this year, the company expects to share the trial design and clinical combination data that informed this planned trial. The company also remains on track to initiate a registrational trial this year with daraxonrasib as adjuvant treatment for patients with resectable PDAC and expects to share the trial design later this year. Based on new clinical data disclosed by the company last quarter indicating that daraxonrasib can be combined productively with pembrolizumab with or without platinum doublet chemotherapy as a first line treatment of patients with RAS mutant NSCLC, the company expects to initiate a Phase 3 registrational trial in this indication in 2026. Generate sufficient data to inform development priorities for the mutant-selective inhibitors elironrasib and zoldonrasib and prepare to initiate one or more pivotal trials either as monotherapy or in a drug combination The company continues to study its mutant-selective inhibitors elironrasib and zoldonrasib as monotherapy and in drug combinations. The company recently reported an updated clinical data set from patients with previously treated KRAS G12C NSCLC treated with elironrasib as monotherapy that showed a highly competitive profile, including differentiated safety and tolerability along with a compelling objective response rate and progression-free survival. The company also showed clinical evidence that elironrasib can be combined productively with pembrolizumab in first line NSCLC patients with an acceptable safety and tolerability profile. Further, the company recently announced that elironrasib received FDA Breakthrough Therapy Designation for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor. The company believes this designation is a recognition of the significant unmet medical need and elironrasib's potential to serve these patients. Currently there are no RAS-targeted inhibitors with full FDA approval for treating patients with KRAS G12C NSCLC. For zoldonrasib, clinical data presented in April demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D NSCLC, which follows encouraging data reported previously in patients with KRAS G12D PDAC. The company expects to initiate one or more pivotal combination trials in 2026 that incorporate either zoldonrasib or elironrasib. Progress earlier stage pipeline, including advancing next-generation innovations from the company's highly productive discovery organization Clinical development of RMC-5127, a RAS(ON) G12V-selective inhibitor, remains on track to reach a clinic-ready stage in 2025 to enable an expected Phase 1 initiation in 2026. The company also continues to invest in collaborations designed to enhance its discovery efforts, recently announcing a drug discovery collaboration with Iambic Therapeutics, in which Iambic will use its cutting-edge AI capabilities to generate customized models through training with Revolution Medicines' proprietary data. This collaboration aims to enhance Revolution Medicines' lead discovery and optimization processes directed against both current and new drug targets to ensure the company continues building a highly impactful and sustainable pipeline. Grow global commercialization and operational capabilities and advance launch readiness The company recently announced a partnership with Royalty Pharma, which provides $2 billion in committed capital to Revolution Medicines upon achievement of agreed-upon milestones through a flexible mix of synthetic royalty and debt instruments. This flexible funding agreement provides the company with strategic agility and ability to secure the resources needed to advance its ambitious global clinical development and commercialization plans. The company continues to grow its commercial and operational capabilities and increase activities in support of a potential launch. 'As we advance our innovative RAS(ON) inhibitors through late-stage development and prepare for potential commercialization, we are scaling the effort to meet the ever-growing opportunities afforded by our pipeline,' said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. 'With our maturing pipeline, organizational capabilities and recently bolstered financial wherewithal, we are on a path toward becoming a fully integrated, global oncology company with an industry-leading franchise of targeted therapies for patients with RAS-addicted cancers.' Other Corporate Updates Building on recently disclosed clinical data supporting combinations of its RAS(ON) inhibitors with pembrolizumab, a leading PD-1 antibody, the company announced that it had entered into a clinical collaboration with Summit Therapeutics in multiple solid tumor settings to evaluate the safety and efficacy of Revolution Medicines' clinical-stage RAS(ON) inhibitors in combination with Summit Therapeutics' ivonescimab, an innovative PD-1 / VEGF bispecific antibody. Financial Highlights Second Quarter Results Cash Position: Cash, cash equivalents and marketable securities were $2.1 billion as of June 30, 2025. This balance includes receipt of the first $250 million royalty monetization tranche from Royalty Pharma. R&D Expenses: Research and development expenses were $224.1 million for the quarter ended June 30, 2025, compared to $134.9 million for the quarter ended June 30, 2024. The increase in expenses was primarily due to increases in clinical trial expenses and manufacturing expenses for daraxonrasib, zoldonrasib and elironrasib, and personnel-related expenses and stock-based compensation expense related to additional headcount. G&A Expenses: General and administrative expenses were $40.6 million for the quarter ended June 30, 2025, compared to $21.7 million for the quarter ended June 30, 2024. The increase was primarily due to increases in personnel-related expenses and stock-based compensation expense associated with additional headcount, and an increase in commercial preparation activities. Net Loss: Net loss was $247.8 million for the quarter ended June 30, 2025, compared to net loss of $133.2 million for the quarter ended June 30, 2024. Financial GuidanceRevolution Medicines is projecting full year 2025 GAAP net loss guidance of between $1.03 billion and $1.09 billion, which includes estimated non-cash stock-based compensation expense of between $115 million and $130 million. WebcastRevolution Medicines will host a webcast this afternoon, August 6, 2025, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). To listen to the live webcast, or access the archived webcast, please visit: Following the live webcast, a replay will be available on the company's website for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered 'forward-looking statements,' including without limitation statements regarding the company's financial projections and guidance; the company's development opportunities, plans and timelines and its ability to build or advance its portfolio and R&D pipeline; progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company's candidates being studied; the company's expectations regarding timing of clinical trial initiation, enrollment and data readouts or disclosures and clinical trial designs; collaborations, including the aims and expected benefits of the Company's collaboration with Iambic; sources of capital, including the availability of capital under the Royalty Pharma arrangement and whether the company achieves the milestones associated with certain payments thereunder. Forward-looking statements are typically, but not always, identified by the use of words such as 'aims,' 'anticipate,' "believe," "estimate," "expect," "plan," 'potential,' 'project,' 'up to,' "will" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company's development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company's programs' development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company's business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on August 6, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events. Revolution Medicines Media & Investor Contact:media@ investors@ REVOLUTION MEDICINES, CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share data)(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 224,134 $ 134,932 $ 429,883 $ 252,953 General and administrative 40,580 21,711 75,591 44,549 Total operating expenses 264,714 156,643 505,474 297,502 Loss from operations (264,714 ) (156,643 ) (505,474 ) (297,502 ) Other income (expense), net: Interest income 22,404 21,487 47,319 45,247 Interest and other income (expense), net (899 ) 16 (909 ) (2,793 ) Change in fair value of warrant liabilities and contingent earn-out shares (4,578 ) 1,907 (2,139 ) 5,812 Total other income, net 16,927 23,410 44,271 48,266 Loss before income taxes (247,787 ) (133,233 ) (461,203 ) (249,236 ) Net loss $ (247,787 ) $ (133,233 ) $ (461,203 ) $ (249,236 ) Net loss per share attributable to common stockholders, basic and diluted $ (1.31 ) $ (0.81 ) $ (2.45 ) $ (1.51 ) Weighted-average common shares used to compute net loss per share, basic and diluted 188,583,288 165,141,936 188,365,805 164,935,542 REVOLUTION MEDICINES, CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, unaudited) June 30, 2025 December 31, 2024 Cash, cash equivalents and marketable securities $ 2,137,171 $ 2,289,299 Working capital (1) 1,991,905 2,163,718 Total assets 2,429,568 2,558,301 Total liabilities 564,199 293,097 Total stockholders' equity 1,865,369 2,265,204 (1) Working capital is defined as current assets less current in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Green Thumb Industries Reports Second Quarter 2025 Results
CHICAGO and VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ('Green Thumb' or the 'Company') (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today reported its financial results for the quarter ended June 30, 2025. Financial results are reported in accordance with U.S. generally accepted accounting principles ('GAAP'), and all currency is in U.S. dollars. Highlights for the second quarter ended June 30, 2025: Revenue of $293.3 million, an increase of 4.7% over the prior year. Cash at quarter end totaled $177 million. GAAP net loss of $0.65 million or $0.01 per basic and diluted share. Excluding the one-time loss of $11.7 million on a sale of assets, GAAP net income would have been $11.0 million or $0.05 per basic and diluted share. Adjusted EBITDA of $82.7 million or 28.2% of revenue. Cash flow from operations of $56 million. Repurchased approximately 5.6 million of the Company's Subordinate Voting Shares for $24 million. See definitions and reconciliation of non-GAAP measures elsewhere in this release. Management Commentary 'The Green Thumb team continues to deliver topline growth despite persistent pricing pressure in many of our key markets. Second quarter 2025 revenue was $293 million, a 5% gain over the comparable period last year. Adjusted EBITDA was $83 million or 28% of revenue and our second quarter cash flow from operations was $56 million. In addition, we bought back 5.6 million shares at an average price of $4.28 per share throughout the quarter,' said Green Thumb Founder, Chairman and Chief Executive Officer Ben Kovler. 'While our stock price continues to serve as a barometer for federal action, we believe Green Thumb has created value not currently reflected by the market due to several factors, including structural issues in the industry. Despite these challenges, we will continue to work to realize that value and continue to build brands Americans love. We are deeply committed to creating long-term value for all our stakeholders; this has always been the Green Thumb story.' Green Thumb President Anthony Georgiadis added, 'The second quarter was very productive for us. We experienced strong market share gains in key states including Illinois, Pennsylvania, New Jersey, Florida, and others. In addition, our team continued preparation for Minnesota's imminent adult-use launch. As we look ahead, we are confident in our team, our strategy, and our financial strength to help us navigate the current market environment.' Second Quarter 2025 Financial Overview Total revenue for the second quarter 2025 was $293.3 million, up 4.7% from the prior year period. Revenue growth in the second quarter was driven primarily by sales from the Company's Consumer Packaged Goods segment, reflecting continued expansion in the adult-use markets in New York and Ohio. Overall retail revenue increased 0.3% versus the second quarter of 2024. Second quarter 2025 comparable sales (stores open at least 12 months) decreased 4.1% versus the prior year on a base of 91 stores. Consumer Packaged Goods gross revenue increased 8.4% versus the second quarter of 2024. Gross profit for the second quarter 2025 was $146.3 million or 49.9% of revenue, down from $150.5 million or 53.7% of revenue over the prior year period. The decline in gross margin percentage was primarily driven by price compression. Total selling, general and administrative expenses for the second quarter 2025 were $106.8 million or 36.4% of revenue, compared to $96.5 million or 34.4% of revenue for the second quarter 2024. The increase in total expenses was primarily attributable to increased costs associated with the opening and operation of new retail stores. Total other expense for the second quarter was $17.1 million versus $1.2 million for the comparable period, primarily due to the loss on the sale of Green Thumb's incredibles intellectual property and hemp business to Agrify. Net loss attributable to the Company for the second quarter was $0.65 million or $0.01 per basic and diluted share, compared to net income of $20.7 million, or $0.09 per basic and diluted share in the prior year period. Excluding the one-time charge of $11.7 million, GAAP net income would have been $11.0 million or $0.05 per basic and diluted share. In the second quarter 2025, EBITDA was $69.1 million or 23.6% of revenue, versus $82.0 million or 29.3% of revenue for the comparable prior year period. Adjusted EBITDA, which excluded non-cash stock-based compensation of $12.0 million and other non-operating adjustments of $1.7 million, was $82.7 million or 28.2% of revenue, down from $93.8 million or 33.5% of revenue for the second quarter 2024. For additional information on the non-GAAP financial measures discussed above, see under 'Non-GAAP Financial Information' below. Balance Sheet and Liquidity As of June 30, 2025, current assets were $405.4 million, including cash and cash equivalents of $176.9 million. Total debt outstanding was $250.0 million. Total basic and diluted weighted average shares outstanding for the three months ended June 30, 2025, were 235.8 million shares. Capital Allocation During the second quarter, the Company repurchased approximately 5.6 million Subordinate Voting Shares for $24 million, at an average price of $4.28 per share. To date, the Company has purchased a total of approximately 13.5 million Subordinate Voting Shares for $108 million, with an average purchase price of $7.96 per share. The Company's remaining authority to repurchase Shares is $15.6 million through September 22, 2025. Non-GAAP Financial Information This press release includes certain non-GAAP financial measures as defined by the U.S. Securities and Exchange Commission. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measure calculated and presented in accordance with GAAP are included in the financial schedules attached to this press release. This information should be considered as supplemental in nature and not as a substitute for, or superior to, any measure of performance prepared in accordance with GAAP. Definitions EBITDA: Earnings before interest, taxes, other income or expense and depreciation and amortization. Adjusted EBITDA: Earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash stock-based compensation, one-time transaction related expenses, or other non-operating costs. Conference Call and Webcast Green Thumb will host a conference call on Wednesday, August 6, 2025, at 5:00 pm Eastern Time to discuss its results for the quarter ended June 30, 2025. The earnings call may be accessed by dialing 844-883-3895 (toll-free) or 412-317-5797 (international). A live audio webcast of the call will also be available on the Investor Relations section of Green Thumb's website at and will be archived for replay. About Green Thumb Industries Green Thumb Industries Inc. ('Green Thumb') is a leading national cannabis consumer packaged goods company and retailer headquartered in Chicago, Illinois. The company manufactures and distributes a portfolio of branded cannabis products, some of which are licensed, including RYTHM, Dogwalkers, incredibles, Beboe, &Shine, Doctor Solomon's and Good Green. Green Thumb also owns and operates RISE Dispensaries, a rapidly growing national retail chain. Green Thumb serves millions of patients and customers each year with a mission to promote well-being through the power of cannabis while giving back to the communities it serves. Established in 2014, Green Thumb has 20 manufacturing facilities and 108 retail stores across 14 U.S. markets, employing approximately 4,800 people. More information is available at Cautionary Note Regarding Forward-Looking Information This press release contains statements that we believe are, or may be considered to be, 'forward-looking statements.' All statements other than statements of historical fact included in this document regarding the prospects of our industry or our prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as 'may,' 'will,' 'expect,' 'intend,' 'estimate,' 'foresee,' 'opportunity,' 'project,' 'potential,' 'risk,' 'anticipate,' 'believe,' 'plan,' 'forecast,' 'continue,' 'suggests' or 'could' or the negative of these terms or variations of them or similar terms or expressions of similar meaning. Furthermore, forward-looking statements may be included in various filings that we make with the Securities and Exchange Commission (the 'SEC'), or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. These known and unknown risks include, without limitation: cannabis remains illegal under U.S. federal law, and enforcement of cannabis laws could change; state regulation of cannabis is uncertain; the Company may not be able to obtain or maintain necessary permits and authorizations; the Company may face limitations on ownership of cannabis licenses; the Company may become subject to U.S. Food and Drug Administration or the U.S. Bureau of Alcohol, Tobacco, Firearms, and Explosives regulation; as a cannabis business, the Company is subject to applicable anti-money laundering laws and regulations and have restricted access to banking and other financial services; the Company may face difficulties acquiring additional financing; the Company operates in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where it conducts business; the Company faces intense competition; the Company faces competition from the illicit market as well as hemp products that are actually or purportedly compliant with the Agricultural Improvement Act of 2018 (the Farm Bill); the Company is dependent upon the popularity and consumer acceptance of its brand portfolio; the Company has limited trademark protections; as a cannabis business, the Company is subject to unfavorable tax treatment and may incur significant tax liability; as a cannabis business, the Company may be subject to civil asset forfeiture; the Company is subject to proceeds of crime statutes; the Company faces exposure to fraudulent or illegal activity; the Company faces risks due to industry immaturity or limited comparable, competitive or established industry best practices; the Company faces risks related to its products; the Company's business is subject to the risks inherent in agricultural operations; the Company faces an inherent risk of product liability and similar claims; the Company's products may be subject to product recalls; the Company may face unfavorable publicity or consumer perception; the Company may be adversely impacted by rising or volatile energy costs and availability; the Company faces risks related to its information technology systems and potential cyber-attacks and security breaches; the Company relies on third-party software providers for numerous capabilities we depend upon to operate, and a disruption of one or more of these systems could adversely affect our business; the Company relies on the expertise of its management team and other employees experienced in the cannabis industry, and the loss of key personnel could negatively affect its business; the Company's voting control is concentrated; the Company's capital structure and voting control may cause unpredictability; and sales of substantial amounts Subordinate Voting Shares by the Company's shareholders in the public market may have an adverse effect on the market price of the Company's Subordinate Voting Shares. Further information on these and other potential factors that could affect the Company's business and financial condition and the results of operations are included in the 'Risk Factors' section of the Company's most recent Annual Report on Form 10-K and elsewhere in the Company's filings with the SEC, which are available on the SEC's website or at Readers are cautioned not to place undue reliance on any forward-looking statements contained in this document, which reflect management's opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements. You are advised, however, to consult any additional disclosures we make in our reports to the SEC. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this document. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release. Investor Contacts: Mathew FaulknerChief Financial OfficerInvestorRelations@ Andy GrossmanEVP, Capital Markets & Investor RelationsInvestorRelations@ 310-622-8257 Media Contact:GTI Communicationsmedia@ Green Thumb Industries Inc. Highlights from Unaudited Interim Condensed Consolidated Statements of OperationsFor the Three Months Ended June 30, 2025, March 31, 2025 and June 30, 2024 Three Months Ended June 30, 2025 March 31, 2025 June 30, 2024 (Unaudited) (Unaudited) (Unaudited) Revenues, Net of Discounts $ 293,257 $ 279,540 $ 280,147 Cost of Goods Sold (147,001 ) (136,265 ) (129,627 ) Gross Profit 146,256 143,275 150,520 Expenses: Total Expenses 106,823 100,793 96,500 Income From Operations 39,433 42,482 54,020 Other Income (Expense): Other Income (Expense), Net (13,989 ) (24 ) 2,464 Interest Income 1,910 2,123 2,314 Interest Expense, Net (5,046 ) (4,865 ) (5,981 ) Total Other Expense (17,125 ) (2,766 ) (1,203 ) Income Before Provision for Income Taxes And Non-Controlling Interest 22,308 39,716 52,817 Provision For Income Taxes 21,576 31,315 31,899 Net Income Before Non-Controlling Interest 732 8,401 20,918 Net Income Attributable To Non-Controlling Interest 1,377 95 206 Net (Loss) Income Attributable To Green Thumb Industries Inc. $ (645 ) $ 8,306 $ 20,712 Net (Loss) Income Per Share - Basic $ (0.01 ) $ 0.04 $ 0.09 Net (Loss) Income Per Share - Diluted $ (0.01 ) $ 0.04 $ 0.09 Weighted Average Number of Shares Outstanding - Basic 235,842,313 236,120,511 237,416,373 Weighted Average Number of Shares Outstanding - Diluted 235,842,313 236,822,468 240,137,922 Green Thumb Industries from the Unaudited Interim Condensed Consolidated Balance Sheet(Amounts Expressed in Thousands of United States Dollars) June 30, 2025 (Unaudited) Cash and Cash Equivalents $ 176,923 Other Current Assets 228,514 Property and Equipment, Net 722,991 Right of Use Assets, Net 240,886 Intangible Assets, Net 462,407 Goodwill 595,619 Other Long-term Assets 120,882 Total Assets $ 2,548,222 Total Current Liabilities $ 179,326 Notes Payable, Net of Current Portion and Debt Discount 234,069 Lease Liabilities, Net of Current Portion 256,807 Other Long-Term Liabilities 78,621 Total Equity 1,799,399 Total Liabilities and Equity $ 2,548,222 Green Thumb Industries Inc. Supplemental Information (Unaudited) Regarding Non-GAAP Financial MeasuresFor the For the Three Months Ended June 30, 2025, March 31, 2025 and June 30, 2024(Amounts Expressed in Thousands of United States Dollars) EBITDA, and Adjusted EBITDA are non-GAAP measures and do not have standardized definitions under GAAP. We define each term as follows: (1) EBITDA is defined as earnings before interest, taxes, other income or expense and depreciation and amortization.(2) Adjusted EBITDA is defined as earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating (income) or costs. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented. Three Months Ended Adjusted EBITDA June 30, 2025 March 31, 2025 June 30, 2024 (Unaudited) (Unaudited) (Unaudited) Net Income Before Noncontrolling Interest (GAAP) $ 732 $ 8,401 $ 20,918 Interest Income (1,910 ) (2,123 ) (2,314 ) Interest Expense, Net 5,046 4,865 5,981 Provision For Income Taxes 21,576 31,315 31,899 Other Expense (Income), Net 13,989 24 (2,464 ) Depreciation and Amortization 29,671 29,411 27,985 Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (non-GAAP measure) $ 69,104 $ 71,893 $ 82,005 Share-based Compensation, Non-Cash 11,966 10,309 8,866 Acquisition, Transaction, and Other Non-Operating (Income) Costs 1,670 3,045 2,925 Adjusted EBITDA (non-GAAP measure) $ 82,740 $ 85,247 $ 93,796 This press release was published by a CLEAR® Verified in to access your portfolio
